Located in Deoksan-eup, Jincheon-gun, Chungcheongbuk-do, Korea, the Jincheon Plant was constructed on a site of 19,968㎡ with a total floor area of 5,636㎡ with 2 floors above ground and 1 floor underground, and started to produce raw materials and finished drugs from completion of construction in 1989. Following the establishment of Jincheon Plant, REYON was selected as a KGMP facility qualified company by the Ministry of Health and Welfare in March 1991 and commenced production of excellent-quality finished pharmaceutical products. In 1994, the company expanded the fermentation plant, which had a total floor area of 5,361㎡ and 3 stories above the ground, and the total gross floor area is now 13,800.18㎡, serving as a solid foundation for mass production of pharmaceutical products.

REYON Pharmaceutical's APIproduction line comprises over 40 different materials, including aminoglycoside antibiotic Arbekacin sulfate, which REYON was the first generic company in the world to successfully produce in 1999 based on its mission to enhance lives and its technology accumulated over 65 years. We supply high value added APIs to pharmaceutical companies in Korea and overseas. REYON Pharmaceutical is recognized for its advanced know-how in synthesis and fermentation technology, and the company continues to contribute not only to the production of excellent drug substances, but also to building the foundation for the pharmaceutical industry.

Our finished product production line is designed to enable flexible production under GMP regulations from warehousing to shipment of drug products. Our oral solids line for the production of high-quality tablets and capsules, and injection line capable of producing ampoules and vials serve as the infrastructure for product development and clinical sample production as well as commercial products, and we also consign production to trusted domestic and overseas pharmaceutical companies.

By executing continuous quality control, quality assurance, and quality improvement activities to supply safe pharmaceutical products to customers, we maintain a quality control system that enables us to produce drug substances and finished products that are safe, stable, and effective.

The Chungju Plant is a cGMP-class global bio & chemical production platform in Daesowon-myeon Chungju City, Chungcheongbuk-do (land area 75,870㎡, building area 14,876㎡). The Chungju Plant, which will be realized through the fusion of REYON Pharmaceutical's manufacturing technology and cutting-edge bio technology, will be the foundation for a new leap forward for REYON to become a specialist in bio and chemical pharmaceuticals.

cGMP (Current Good Manufacturing Practice) is a stringent group of pharmaceutical manufacturing and quality control standards recognized by the US Food and Drug Administration, and is also referred to as "advanced GMP" in Korea. The Chungju plant has been constructed as a comprehensive production platform for cGMP-class bio & chemical drugs, and based on state-of-the-art production facilities, REYON has been producing and supplying high-quality pharmaceuticals not only in Korea but also in overseas markets.

The Chungju Plant is a modular plant capable of responding quickly and flexibly to production of additional formulation depending on changes in the pharmaceutical industry and demand for the production. It is possible to establish flexible and fast processes, add production lines for various formulations, and add separate production areas without the need for additional design.

We have established an integrated IT system management system for data integrity, which makes effective and systematic management of pharmaceuticals possible with a Central Control Room (CCR), various IT systems, and automated warehouse, thus guaranteeing stable quality during production, storage, and distribution.